Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication

Helicobacter

Volumn 18, Issue 2, 2013, Pages 117-123

  Sheu, Bor Shyang ^a   Tsai, Yu Ching ^a   Wu, Chung Tai ^a   Chang, Wei Lun ^a   Cheng, Hsiu Chi ^a   Yang, Hsiao Bai ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Celecoxib; Cyclooxygenase 2; H. pylori; Intestinal metaplasia

Indexed keywords

AMOXICILLIN; CELECOXIB; CLARITHROMYCIN; ESOMEPRAZOLE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOCHEMISTRY; INTESTINE METAPLASIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINES; MALE; METAPLASIA; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84875023974     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12013     Document Type: Article

References (18)

1. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
2. Sheu BS, Yang HB, Sheu SM, Huang AH, Wu JJ. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003;9:5245-51.
3. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659-72.
4. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
5. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
6. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
7. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;25:455-61.
8. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009;104:1642-9.
9. Hung KH, Wu JJ, Yang HB, Su LJ, Sheu BS. Host Wnt/β-catenin pathway triggered by H. pylori correlates to the regression of gastric intestinal metaplasia after H. pylori eradication. J Med Microbiol 2009;58:567-76.
10. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
11. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999;94:1218-23.
12. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-35.
13. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.
14. Hung KH, Yang HB, Cheng HC, Wu JJ, Sheu BS. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 2010;25:48-53.
15. Hung KH, Hung HW, Yang HB, Lu CC, Wu JJ, Sheu BS. Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection. Helicobacter 2009;14:580-7.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
17. Chang WL, Yang HB, Cheng HC, Chuang CH, Lu PJ, Sheu BS. Increased gastric osteopontin expression by Helicobacter pylori infection can correlate with more severe gastric inflammation and intestinal metaplasia. Helicobacter 2011;16:217-24.
18. Cheung TK, Xia HH, Wong BC. Helicobacter pylori eradication for gastric cancer prevention. J Gastroenterol 2007;42(Suppl 17):10-5.